BioCardia Files 8-K
Ticker: BCDA · Form: 8-K · Filed: Sep 18, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
BioCardia filed an 8-K on 9/18/24. Standard update.
AI Summary
BioCardia, Inc. filed an 8-K on September 18, 2024, to report other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates BioCardia is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, typically used for significant corporate events or financial updates, but the content itself doesn't indicate immediate risk.
Key Numbers
- 001-38999 — SEC File Number (Identifier for the company's filings)
- 23-2753988 — IRS Employer Identification No. (Tax identification number)
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- September 18, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of September 18, 2024.
When was BioCardia, Inc. previously known by another name?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., with a name change date of June 16, 2011.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What is BioCardia, Inc.'s principal executive office address?
The principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
What is the SIC code for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code for BioCardia, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-09-18 08:30:48
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20240918_8k.htm (8-K) — 25KB
- ex_725189.htm (EX-99.1) — 10KB
- 0001437749-24-029412.txt ( ) — 167KB
- bcda-20240918.xsd (EX-101.SCH) — 3KB
- bcda-20240918_def.xml (EX-101.DEF) — 11KB
- bcda-20240918_lab.xml (EX-101.LAB) — 15KB
- bcda-20240918_pre.xml (EX-101.PRE) — 11KB
- bcda20240918_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 18, 2024, BioCardia, Inc. (the "Company") issued a press release announcing that is has received formal written notice from The Nasdaq Stock Market, LLC's office of General Counsel ("Nasdaq") that the Company has demonstrated compliance with Listing Rule 5550(b)(1) (the "Equity Rule") of the Nasdaq Stock Market, as required by the Hearings Panel's ("Panel") decision dated May 13, 2024. Accordingly, the Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter. The Company understands that Nasdaq will continue to monitor Company's ongoing compliance with The Nasdaq Stock Market's continued listing requirements. A copy of the press release is attached as Exhibit 99.1 to the current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated September 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 18, 2024